Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review

ABSTRACT

Objectives

Due to its anti-angiogenic properties, trebananib is frequently employed in the treatment of cancer patients, particularly those with ovarian cancer. We conducted a meta-analysis to assess the efficacy and safety profile of trebananib in combination with other drugs for treating both ovarian and non-ovarian cancer patients.

Methods

Our search encompassed PubMed, Medline, Cochrane, and Embase databases, with a focus on evaluating study quality. Data extraction was conducted from randomized controlled trials (RCTs), and RevMan 5.3 facilitated result analysis.

Results

Combining trebananib with other drugs extended progression-free survival (PFS) [HR 0.81, (95%CI: 0.65, 0.99), p = 0.04] and overall survival (OS) [HR 0.88, (95%CI: 0.79, 1.00), p = 0.04] in ovarian cancer patients. Ovarian cancer patients exhibited a higher objective response rate (ORR) with trebananib compared to non-ovarian cancer cohorts. Moreover, the incorporation of trebananib into the standard treatment regimen for malignant tumors did not significantly elevate drug-related adverse events [RR 1.05, (95% CI: 1.00, 1.11), p = 0.05].

Conclusion

Trebananib plus other drugs can improve the PFS, OS and ORR in patients with cancer, especially ovarian cancer. Our recommendation is to use trebananib plus other drugs to treat advanced cancer, and to continuously monitor and manage drug-related adverse events.

Registration

PROSPERO (No. CRD42023466988)

KEYWORDS:

• Ovarian cancer
• Trebananib
• anti-angiogenesis
• efficacy
• adverse events

Author contributions

Study design and manuscript writing were done by J Zhang and J Su. Literature search and data collection were done by J Su and Y Zhou. Figures, table, data analysis by J Zhang, J Su and J Lu. Manuscript revisions were done by J Lu and Y Zhou. Manuscript finalization and funds support were done by J Lu. All authors read and approved the final manuscript.

Acknowledgments

Figure 1 was made using figdraw.

Availability of data and materials

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14737140.2024.2377793

Additional information

Funding

This paper was funded by the Construction Fund of Medical Key Disciplines of Hangzhou. Oncology Therapeutics (Joint Unit), platform code (OO20200385), Expense reimbursement (2020SJZDXK04) and by the Zhejiang Lin Shengyou famous Traditional Chinese Medicine expert inheritance studio project (GZS202002).